Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Piotr Parcheta"'
Publikováno v:
Przegląd Dermatologiczny, Vol 101, Iss 5, Pp 390-396 (2014)
Introduction. Psoriasis is a chronic inflammatory disease affecting approximately 2% of the population. Biologic agents are the new treatment options for patients with moderate to severe plaque psoriasis who have failed traditional systemic therapies
Externí odkaz:
https://doaj.org/article/12cf3633d5c343109d1b571e8afe02c8
Publikováno v:
Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii
Advances in Dermatology and Allergology, Vol 37, Iss 4, Pp 468-474 (2019)
Advances in Dermatology and Allergology, Vol 37, Iss 4, Pp 468-474 (2019)
Non-alcoholic fatty liver disease (NAFLD) is the most common liver pathology in the western countries. Psoriatic patients are at higher risk of having NAFLD, and at higher risk of experiencing a more severe form of the disease with poorer outcomes. T
Publikováno v:
Przegląd Dermatologiczny, Vol 101, Iss 5, Pp 390-396 (2014)
Introduction. Psoriasis is a chronic inflammatory disease affecting approximately 2% of the population. Biologic agents are the new treatment options for patients with moderate to severe plaque psoriasis who have failed traditional systemic therapies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e801812eb0bc2665aea68e1faac7151d
http://www.termedia.pl/Recurrent-erythema-nodosum-and-pulmonary-lymph-node-tuberculosis-in-a-patient-treated-for-psoriatic-arthritis-and-psoriasis-with-TNF-inhibitors,56,23699,1,1.html
http://www.termedia.pl/Recurrent-erythema-nodosum-and-pulmonary-lymph-node-tuberculosis-in-a-patient-treated-for-psoriatic-arthritis-and-psoriasis-with-TNF-inhibitors,56,23699,1,1.html
Autor:
Lidia Rudnicka, Wiesław Kryczka, Adriana Rakowska, Elżbieta Halina Kłujszo, Dorota Zarębska-Michaluk, Anna B. Witkowska, Ewa Ochwanowska, Piotr Parcheta
Publikováno v:
Journal of Dermatological Case Reports. 8
Combination therapy with pegylated interferon, ribavirin and a first-generation NS3/4A protease inhibitor, telaprevir or boceprevir, is the new strategy for treatment of genotype 1 chronic hepatitis C virus infection. This combination improves therap
Publikováno v:
Kardiologia polska. 67(11)
A 77-year-old female in severe emotional distress was admitted to Coronary Care Unit with typical features of acute coronary syndrome, namely severe chest pain, high cardiac necrosis markers and ST-elevation in ECG. Due to the lack of significant cha